Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 0.65
(-0.31%)
SEK 0.65
(-0.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -49.93 Million SEK | -69.31% |
| 2022 | -29.49 Million SEK | 58.25% |
| 2021 | -70.64 Million SEK | -313.73% |
| 2020 | -17.07 Million SEK | -103.76% |
| 2019 | -8.38 Million SEK | -211.52% |
| 2018 | -2.69 Million SEK | -81.88% |
| 2017 | -1.47 Million SEK | 93.52% |
| 2016 | -22.83 Million SEK | -275.08% |
| 2015 | -6.08 Million SEK | 47.82% |
| 2014 | -11.66 Million SEK | -715.11% |
| 2013 | 1.89 Million SEK | 279.58% |
| 2012 | 499.76 Thousand SEK | 608.16% |
| 2011 | 70.57 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -39.89 Million SEK | 20.11% |
| 2024 Q3 | -31.71 Million SEK | 11.9% |
| 2024 Q2 | -36 Million SEK | 9.74% |
| 2023 Q2 | -15.5 Million SEK | 43.09% |
| 2023 Q4 | -49.93 Million SEK | 9.33% |
| 2023 Q3 | -55.07 Million SEK | -255.23% |
| 2023 FY | -49.93 Million SEK | -69.31% |
| 2023 Q1 | -27.24 Million SEK | 7.63% |
| 2022 Q2 | -41.44 Million SEK | 27.27% |
| 2022 FY | -29.49 Million SEK | 58.25% |
| 2022 Q4 | -29.49 Million SEK | -10.34% |
| 2022 Q3 | -26.72 Million SEK | 35.5% |
| 2022 Q1 | -56.98 Million SEK | 19.34% |
| 2021 Q3 | -85.7 Million SEK | -1740.81% |
| 2021 Q1 | -13.29 Million SEK | 22.14% |
| 2021 Q4 | -70.64 Million SEK | 17.58% |
| 2021 FY | -70.64 Million SEK | -313.73% |
| 2021 Q2 | -4.65 Million SEK | 64.98% |
| 2020 Q1 | -10.16 Million SEK | -21.26% |
| 2020 Q2 | -1.45 Million SEK | 85.71% |
| 2020 Q4 | -17.07 Million SEK | 51.79% |
| 2020 Q3 | -35.41 Million SEK | -2339.12% |
| 2020 FY | -17.07 Million SEK | -103.76% |
| 2019 Q4 | -8.38 Million SEK | 24.88% |
| 2019 Q1 | -13.82 Million SEK | -413.75% |
| 2019 FY | -8.38 Million SEK | -211.52% |
| 2019 Q2 | -4.41 Million SEK | 68.02% |
| 2019 Q3 | -11.15 Million SEK | -152.46% |
| 2018 Q2 | -27.16 Million SEK | -523.22% |
| 2018 FY | -2.69 Million SEK | -81.88% |
| 2018 Q4 | -2.69 Million SEK | 79.0% |
| 2018 Q3 | -12.81 Million SEK | 52.83% |
| 2018 Q1 | -4.35 Million SEK | -194.66% |
| 2017 Q4 | -1.47 Million SEK | 14.06% |
| 2017 FY | -1.47 Million SEK | 93.52% |
| 2017 Q3 | -1.72 Million SEK | 72.38% |
| 2017 Q2 | -6.23 Million SEK | 54.34% |
| 2017 Q1 | -13.64 Million SEK | 40.23% |
| 2016 Q1 | -17.63 Million SEK | -189.7% |
| 2016 Q4 | -22.83 Million SEK | 25.37% |
| 2016 FY | -22.83 Million SEK | -275.08% |
| 2016 Q3 | -30.6 Million SEK | -170.17% |
| 2016 Q2 | -11.32 Million SEK | 35.78% |
| 2015 Q3 | -13.65 Million SEK | -1527.41% |
| 2015 Q4 | -6.08 Million SEK | 55.41% |
| 2015 FY | -6.08 Million SEK | 47.82% |
| 2015 Q2 | -839 Thousand SEK | 87.96% |
| 2015 Q1 | -6.96 Million SEK | 40.28% |
| 2014 Q4 | -11.66 Million SEK | -553.85% |
| 2014 FY | -11.66 Million SEK | -715.11% |
| 2014 Q1 | 603.47 Thousand SEK | -68.19% |
| 2014 Q2 | -1.01 Million SEK | -267.7% |
| 2014 Q3 | 2.57 Million SEK | 354.05% |
| 2013 Q4 | 1.89 Million SEK | 0.0% |
| 2013 Q1 | 2489.00 SEK | 0.0% |
| 2013 FY | 1.89 Million SEK | 279.58% |
| 2012 FY | 499.76 Thousand SEK | 608.16% |
| 2011 FY | 70.57 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -135.249% |
| Amniotics AB (publ) | -5.63 Million SEK | -786.612% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -2210.689% |
| BioArctic AB (publ) | -606.58 Million SEK | 91.768% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1024.704% |
| Saniona AB (publ) | 40.44 Million SEK | 223.455% |
| Simris Alg AB (publ) | 85.07 Million SEK | 158.694% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 85.033% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -5309.967% |
| NextCell Pharma AB | -46.79 Million SEK | -6.718% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -69.942% |
| AcouSort AB (publ) | -23.98 Million SEK | -108.18% |
| Active Biotech AB (publ) | -33.2 Million SEK | -50.404% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 0.174% |
| Camurus AB (publ) | -1.16 Billion SEK | 95.715% |
| Cantargia AB (publ) | -139.74 Million SEK | 64.268% |
| Genovis AB (publ.) | -43.94 Million SEK | -13.639% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 40.371% |
| Mendus AB (publ) | -96.29 Million SEK | 48.144% |
| Kancera AB (publ) | -45.69 Million SEK | -9.284% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 39.255% |
| LIDDS AB (publ) | -13.51 Million SEK | -269.553% |
| Lipum AB (publ) | -8.46 Million SEK | -489.888% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -56.401% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 193.82% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -161.983% |
| OncoZenge AB (publ) | -12.62 Million SEK | -295.454% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 130.067% |
| Xintela AB (publ) | -7.8 Million SEK | -539.442% |
| Ziccum AB (publ) | -2.13 Million SEK | -2236.64% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 63.855% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 61.439% |
| CombiGene AB (publ) | -101.44 Million SEK | 50.775% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 39.169% |
| Intervacc AB (publ) | -88.16 Million SEK | 43.36% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 343.462% |
| Corline Biomedical AB | -17.01 Million SEK | -193.522% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 40.372% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -26.794% |
| Aptahem AB (publ) | 2.9 Million SEK | 1816.746% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 84.825% |
| Fluicell AB (publ) | -2.76 Million SEK | -1707.239% |
| Biovica International AB (publ) | -58.73 Million SEK | 14.987% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -10.432% |
| Abliva AB (publ) | -57.24 Million SEK | 12.764% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 74.353% |
| 2cureX AB (publ) | -13.4 Million SEK | -272.558% |
| I-Tech AB | -83.26 Million SEK | 40.028% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 137.068% |
| Cyxone AB (publ) | -16.67 Million SEK | -199.544% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 10.65% |
| Biosergen AB | -1.88 Million SEK | -2551.832% |
| Nanologica AB (publ) | -9.38 Million SEK | -431.892% |
| SynAct Pharma AB | -61.75 Million SEK | 19.146% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -133.173% |
| BioInvent International AB (publ) | -236.3 Million SEK | 78.869% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -277.453% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 25.383% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -863.806% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -140.148% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1580.148% |